Appili Therapeutics Inc Class A (TSE:APLI)
TSX:APLI
Want to see TSE:APLI full AI Analyst Report?
APLI Stock Chart & Stats
C$0.02
>-C$0.01(-14.29%)
At close: 4:00 PM EST
C$0.02
>-C$0.01(-14.29%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume36.33K
Average Volume (3M)72.91K
Market Cap
C$1.93M
Enterprise ValueC$14.17M
Total Cash (Recent Filing)C$212.75K
Total Debt (Recent Filing)C$12.46M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Infectious-disease Focused PipelineAppili’s concentrated clinical-stage pipeline in antifungal and antibacterial therapies targets structurally persistent needs in infectious disease and preparedness. This focus aligns with ongoing public health priorities and potential non-dilutive government funding, giving durable strategic optionality if trials progress.
Improving Operating Cash BurnTrailing-twelve-month cash burn improving to near-breakeven materially reduces immediate financing pressure versus prior years. If sustained, this enhances runway and the firm’s ability to advance clinical programs without immediate large financings, strengthening near-term execution capacity.
Lean Cost StructureA very small employee base supports low fixed overhead and capital-efficient R&D operations typical of pre-commercial biotechs. This lean structure can extend runway, permit targeted outsourcing, and enable focused resource allocation to core clinical assets over a multimonth horizon.
Bears Say
Stressed Balance SheetNegative equity and material debt relative to assets sharply constrain financial flexibility, increase refinancing and covenants risk, and elevate the likelihood of dilutive financings. This weak solvency profile is a durable structural vulnerability for a pre-commercial biotech funding multi-stage trials.
Minimal Revenue And Persistent LossesThe company generates negligible recurring revenue while reporting deep net losses, meaning it cannot self-fund development. Over the medium term this elevates execution risk as programs depend on external capital or partnerships to sustain clinical development and regulatory activities.
Inconsistent Cash GenerationVolatile and negative free cash flow growth undermines predictability of funding for multi-stage trials. Inconsistent cash generation increases the probability of disruptive financing rounds or delayed programs, harming long-term program continuity and strategic planning.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$1.93M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 65 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.